A randomized phase II/III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non–small cell lung cancer: TORG1630.
Y Kawashima, Y Taniguchi, T Shimokawa, Y Takiguchi… - 2022 - ascopubs.org
9030 Background: Immuno-checkpoint inhibitor (ICI) monotherapy is a standard second-line
treatment for non-small-cell lung cancer (NSCLC). Addition of a cytotoxic agent to ICI may …
treatment for non-small-cell lung cancer (NSCLC). Addition of a cytotoxic agent to ICI may …
[HTML][HTML] 604 Clinical and molecular findings from a randomized phase II study of epigenetic priming with azacitidine and entinostat followed by nivolumab in …
KA Marrone, BV Landon, MJ Topper, HL Tsai, A Balan… - 2023 - jitc.bmj.com
Background Epigenetic targeting agents with immunotherapy represents an ongoing
combinatorial approach in non-small cell lung cancer (NSCLC). Preclinical studies have …
combinatorial approach in non-small cell lung cancer (NSCLC). Preclinical studies have …
Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of …
Background: CheckMate 026 is a randomized trial of nivolumab monotherapy versus
platinum doublet chemotherapy in patients with untreated stage IV or recurrent non-small …
platinum doublet chemotherapy in patients with untreated stage IV or recurrent non-small …
[HTML][HTML] Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?
H West - Translational Lung Cancer Research, 2014 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2014; 3
(6): 400-402 www. tlcr. org discontinued therapy, 11 of whom (55%) for disease progression …
(6): 400-402 www. tlcr. org discontinued therapy, 11 of whom (55%) for disease progression …
[HTML][HTML] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution
M Salati, C Baldessari, B Cerbelli… - … Lung Cancer Research, 2018 - ncbi.nlm.nih.gov
Horn and colleagues (11) reported a 2-year followup update on nivolumab in previously
treated NSCLC by pooling together data from both CheckMate-017 and-057, for squamous …
treated NSCLC by pooling together data from both CheckMate-017 and-057, for squamous …
New targeted treatments for non-small-cell lung cancer–role of nivolumab
G Zago, M Muller, M van den Heuvel… - Biologics: Targets and …, 2016 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) is often diagnosed at an advanced stage of disease,
where it is no longer amenable to curative treatment. During the last decades, the survival …
where it is no longer amenable to curative treatment. During the last decades, the survival …
Can previous chemotherapy affect the outcome of nivolumab treatment in non-small cell lung cancer?
M Svaton, M Bratova, L Koubkova, O Fischer… - Anticancer …, 2022 - ar.iiarjournals.org
Aim: This study compared the results of nivolumab treatment in patients with pulmonary
adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods …
adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods …
[HTML][HTML] Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib …
S Kanda, K Goto, H Shiraishi, E Kubo, A Tanaka… - Annals of …, 2016 - Elsevier
In this phase Ib study, four combination therapies of nivolumab 10 mg/kg and standard
chemotherapy (cisplatin/gemcitabine, cisplatin/pemetrexed, carboplatin/paclitaxel …
chemotherapy (cisplatin/gemcitabine, cisplatin/pemetrexed, carboplatin/paclitaxel …
P1. 15-05 Nintedanib in combination with nivolumab in pretreated patients with advanced adenocarcinoma of the lung (AIO-TRK-0117 phase IB/II trial)
M Reck, P Sadjadian, C Waller, K Kambartel… - Journal of Thoracic …, 2022 - jto.org
Methods In this multi-center, open-label, single arm, phase Ib trial patients with advanced or
metastatic non-squamous NSCLC of adenocarcinoma histology after failure of first-or …
metastatic non-squamous NSCLC of adenocarcinoma histology after failure of first-or …
Efficacy and safety of nivolumab for cytotoxic chemotherapy unfit patients with advanced non-small cell lung cancer: A phase II study
Y Okuma, S Kitano, K Watanabe, M Yomota… - Annals of …, 2018 - annalsofoncology.org
Background: This single-center phase II study aimed to examine the efficacy and feasibility
of nivolumab for patients with advanced non-small cell lung cancer (NSCLC) who were …
of nivolumab for patients with advanced non-small cell lung cancer (NSCLC) who were …